




UNC
ESHELMAN
SCHOOL OF PHARMACY



MML
UNC.EDU

Biomedical Knowledge Graphs: Development and Application to Drug Discovery and Repurposing.


Alexander Tropsha
UNC Eshelman School of
Pharmacy



Biomedical Data Translator


“Two hundred years ago, chemists created a comprehensive enumeration of the elements and systematic relationships among them. We envision the Translator doing the same for translational science.”

— Christopher P. Austin, MD, director of NCATS, with Christine M. Colvis, PhD, Noel T. Southall, PhD



Enhance (but not replace) human reasoning, move beyond symptom-based definitions of disease toward a more mechanistic understanding

From Data to Serendipity




Scientific literature as a source of data: Swanson's ABC approach to drug discovery via text mining*

Don R. Swanson

American information scientist



Vasodilation
Spreading cortical depression
Platelet aggregation




*Swanson DR. Medical literature as a potential source of new knowledge. Bull Med Libr Assoc 1990;78(1):29–37

Chemotext (chemotext.mml.unc.edu)



MML
UNC.EDU

- A publicly-available Web server that mines the entire PubMed using Medline Subject Heading (MeSH) terms



- » Data retrieved from the MEDLINE/PubMed Baseline Repository (MBR)
- » Chemotext database contains ca. 30M articles and 100K connections (vertices) between terms
- » Connections are made based on MeSH terms
 - » Chemical terms = A
 - » Protein/Pathway terms = B
 - » Disease terms = C

- Mining PubMed affords rapid identification of connections between vertices and enabling new inferences of such connections


MeSH terms

[Airway Remodeling/physiology*](#)
[Animals](#)
[Asthma/chemically induced](#)
[Asthma/metabolism](#)
[Asthma/physiopathology*](#)
[Benzamides/pharmacology](#)
[Bronchi/drug effects](#)
[Bronchi/metabolism](#)
[Bronchi/pathology](#)
[Bronchial Hyperreactivity/chemically induced](#)
[Bronchial Hyperreactivity/metabolism](#)
[Bronchial Hyperreactivity/physiopathology*](#)
[Cells, Cultured](#)
[Chemokine CCL2/metabolism](#)
[Disease Models, Animal](#)
[Female](#)
[Humans](#)
[Imatinib Mesylate](#)
[In Vitro Techniques](#)
[Interleukin-13/metabolism](#)
[Male](#)
[Mice](#)
[Mice, Inbred C57BL](#)
[Mice, Knockout](#)
[Myocytes, Smooth Muscle/pathology](#)
[Myocytes, Smooth Muscle/physiology*](#)
[Ovalbumin/adverse effects](#)
[Piperazines/pharmacology](#)
[Proliferating Cell Nuclear Antigen/metabolism](#)
[Protein Kinase Inhibitors/pharmacology](#)
[Proto-Oncogene Proteins c-abl/deficiency](#)
[Proto-Oncogene Proteins c-abl/genetics](#)
[Proto-Oncogene Proteins c-abl/physiology*](#)
[Pyrimidines/pharmacology](#)

Shared Terms Module



- Two query terms are input, and co-occurring terms that are shared between the queries are returned.



Home Find Connected Terms **Find Shared Terms** Path Search Find Articles

Asthma

Gastrointestinal Stromal Tumor

Search

Click to Include Subterms

Terms	Same Article	Asthma Only	Gastrointestinal Stromal Tumor Only
Proto-Oncogene Proteins c-kit	0	16	1104
RNA, Messenger	0	1016	46
Antibodies, Monoclonal	0	937	32
Inflammation Mediators	0	874	1
Interferon-gamma	0	863	3
Blood Proteins	0	787	1

View CSV

CSV with pmids

Proteins-Pathways-Intermediaries-Other

Date After: mm/dd/yyyy

Date Before: mm/dd/yyyy

Filter


Establishing Clinical Outcomes Pathways (COPs) of drug action



- COPs explain how a drug elicits its effect on a disease
- Chemotext can be used to elucidate COPs




Translator System Architecture



Simple application: A Knowledge Graph of Exposures, Genes, Drugs, and Diagnoses



Airborne pollutant exposures




Genes

Drug exposures

ROBOKOP (Reasoning Over Biological Objects in Knowledge Oriented Pathways): High-level Concepts Connected by Knowledge Sources

Robokop.renci.org




- Current KG includes ca. 600K nodes and 12+M edges.

“Why does imatinib help people with asthma?”

“Why does clonidine interact with propranolol?”

“Why is sickle cell disease protective against malaria?”



Assertions on relationship & supportive evidence

Bizon C, Cox S, Balhoff J, Kebede Y, Wang P, Morton K, Fecho K, Tropsha A. ROBOKOP KG and KGB: Integrated Knowledge Graphs from Federated Sources. *J Chem Inf Model*. 2019, 59(12):4968-4973

Morton K, Wang P, Bizon C, Cox S, Balhoff J, Kebede Y, Fecho K, Tropsha A. ROBOKOP: An Abstraction Layer and User Interface for Knowledge Graphs to Support Question Answering. *Bioinformatics*. 2019 35(24):5382-5384

Case study: query ROBOKOP for carbon monoxide – multiple sclerosis association.

A.

Natural Language Question


What genes might mediate the association between workplace exposure to carbon monoxide and multiple sclerosis?

B.

Machine Question or Meta-Graph




C.



D. Answer Table

Answers Table [Aggregate Graph](#) [Download](#)

Answer Set			
n0: Chemical Substance	n1: Gene	n2: Disease	Rank
carbon monoxide	Tumor necrosis factor	Multiple sclerosis	0.096
carbon monoxide	BDNF		0.090
carbon monoxide	IL10		0.090
carbon monoxide	Beta-nerve growth factor		0.089
carbon monoxide	IRF8		0.088
carbon monoxide	Calcium-activated potassium channel subunit		0.067



```
graph LR; TNF[Tumor necrosis factor] -- 658 --> MS[Multiple sclerosis]; CO[carbon monoxide] -- 44 --> TNF; CO -- 25 --> MS; CO -- 44 --> MS; TNF -- 44 --> CO; MS -- 25 --> CO;
```







COPs built using knowledge graphs



Ketamine	N-Methyl-D-Aspartate	Neurotransmission	Neurons	Central Nervous System	Depressive Disorder
Glipizidine	Potassium ATP channel	Potassium ion transport	Beta cells	Liver	Diabetes Mellitus, Type2
Maraviroc	C-C chemokine receptor type 5	Cell-cell signaling	Leukocytes	Immune System	Acquired Immunodeficiency Syndrome
Mizolastine	Histamine H1 receptor	Cellular response to histamine	Mast Cells	Immune System	Rhinitis, Allergic, Seasonal
Dipyridamole	Equilibrative nucleoside transporter	Nucleoside transport	Blood Platelets	Circulatory System	Thrombosis


Clinical Outcome Pathways for known drugs and their indications



<u>FDA Approved Drugs</u>	<u>Molecular Initiating Events</u>	<u>Intermediate Events</u>	<u>Clinical Outcomes</u>
 <p>Metformin</p>	 <p>AMPK Activation</p>	<ol style="list-style-type: none"> 1. Inhibition of glucagon-induced increase in cAMP concentration 2. Decreased gluconeogenesis in the liver 	<p>Decreased insulin tolerance, and better control of blood glucose levels in patients with type II diabetes mellitus</p>
 <p>Natalizumab</p>	 <p>Leukocyte α4-integrin Natalizumab α4-integrin Inhibition</p>	<ol style="list-style-type: none"> 1. Inhibition of α-4-integrin binding to VCAM receptors on epithelial cells of blood-brain barrier 2. Decreased migration of lymphocytes into CNS 	<p>Decreased adaptive neuroimmune response, which decreases symptoms and disease progression in patients with multiple sclerosis</p>
 <p>Diazepam</p>	 <p>GABA_A Receptor Modulation</p>	<ol style="list-style-type: none"> 1. Increased response to GABAergic signaling in CNS 2. Enhanced hyperpolarization of CNS neurons leading to neuronal depression 	<p>Symptom reduction in patients with generalized anxiety disorder and/or panic disorder</p>

Clinical Outcome Pathways for known drugs and proposed indications (*i.e.*, repurposing)


COP for the approved indication for famotidine, gastroesophageal reflux disorder (GERD)




Proposed COP to explain the clinical observation that famotidine reduces COVID-19–related mortality

Knowledge mining approaches to find synergistic drug combinations against COVID-19

Bobrowski et al, Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro. *Mol Ther.* **2021** Feb 3;29(2):873-885. DOI: 10.1016/j.ymthe.2020.12.016




Example of a rationale behind drug mixture selection





Korn et al., COVID-KOP: Integrating Emerging COVID-19 Data with the ROBOKOP Database. ChemRxiv. 2020 Jun 18.

doi:10.26434/chemrxiv.12462623.

Bobrowski et al, Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro. Mol Ther. 2021 Feb 3;29(2):873-885. DOI: 10.1016/j.ymthe.2020.12.016



Experimentally confirmed pairs of synergistic or antagonistic drug combinations (CPE assay, NCATS)



Example: Nitazoxanide/Amodiaquine synergistic combination

Summary



MML
UNC.EDU

- Accumulation of multiple biomedical datasets creates new opportunities for data integration and knowledge mining
- Knowledge graph provide powerful means to mine pathways connecting biomedical entities of interest
- Elucidation of Clinical Outcome Pathways supports novel drug repurposing hypotheses
- Emerging application of machine learning approaches to knowledge graph mining accelerates the discovery of unknown biological pathways such as those linking drugs and diseases

Acknowledgements



Principal Investigator

Alexander Tropsha

Postdoctoral Fellows

Vinicius Alves
Cleber Melo-Filho

Collaborators: DT/ROBOKOP

Research Professors

Alexander Golbraikh
Eugene Muratov

Graduate students

Andrew Thieme
Dan Korn
Josh Hochuli

RENCI/SOM:

Stan Ahalt
Kara Fecho
Chris Bizon
Steve Cox
David Peden
Emily Pfaff

COVAR:

Kenny Morton
Patrick Wang

MAJOR FUNDING

NIH

- 1U01CA207160
- R01-GM114015
- 5U54CA198999
- 1OT3TR002020
- OT2TR002514

ONR

- N00014-16-1-2311